Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

MBX Biosciences (MBX) Research & Development (2023 - 2026)

MBX Biosciences has reported Research & Development over the past 4 years, most recently at $18.5 million for Q1 2026.

  • Quarterly results put Research & Development at $18.5 million for Q1 2026, down 17.55% from a year ago — trailing twelve months through Mar 2026 was $75.2 million (up 9.39% YoY), and the annual figure for FY2025 was $79.2 million, up 37.87%.
  • Research & Development reached $18.5 million in Q1 2026 per MBX's latest filing, down from $19.8 million in the prior quarter.
  • Across five years, Research & Development topped out at $22.4 million in Q1 2025 and bottomed at $7.7 million in Q4 2023.
  • Median Research & Development over the past 4 years was $16.7 million (2024), compared with a mean of $15.6 million.
  • The largest annual shift saw Research & Development soared 102.78% in 2025 before it dropped 17.55% in 2026.
  • Over 4 years, Research & Development stood at $7.7 million in 2023, then soared by 97.01% to $15.2 million in 2024, then grew by 29.8% to $19.8 million in 2025, then dropped by 6.5% to $18.5 million in 2026.
  • Business Quant data shows Research & Development for MBX at $18.5 million in Q1 2026, $19.8 million in Q4 2025, and $19.3 million in Q3 2025.